Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
MarketBeat

REVEALED: Lineage cell therapeutics q1 earnings call highlights - The Real Truth

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in geographic atrophy, a newly launched corneal endothelial cell program called COR1, and ongoing manufacturing initiatives built around its AlloSCOPE platform.

Chief Executive Officer Brian Culley said the company remains confident in the potential for OpRegen, its retinal pigment epithelium cell transplant program partnered with Roche and Genentech, to advance into a multi-center controlled trial. He noted that Roche and Genentech recently described OpRegen as a potentially disease-modifying treatment, language he characterized as notable because geographic atrophy in dry age-related macular degeneration is a progressive condition.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.